



## Synthesis and Structural Elucidation of 1, 4 Dihydropyrimido [1, 2-a] Benzimidazole

Kaushik Joshi <sup>a\*</sup>, Vikas Chauhan <sup>b</sup>, Hardik Bhatt <sup>c</sup> and Nikunj Dave <sup>c</sup>

<sup>a</sup> Department of Chemistry, D K V Arts and Science College, Jamnagar-361008 Gujarat, India.

<sup>b</sup> JJT University, Rajasthan, India.

<sup>c</sup> OM College of Science and PG Center, Junagadh-362310 Gujarat, India.

### Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

### Article Information

DOI: 10.9734/AJOCS/2022/v11i119112

### Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here:

<https://www.sdiarticle5.com/review-history/81384>

Original Research Article


Received 02 November 2021

Accepted 04 January 2022

Published 05 January 2022

### ABSTRACT

Considering various biomedical significance & with a view of pharmacological actions of compound belong to this class, new series of N-(substituted phenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1,6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1,4-dihydro pyrimido [1, 2-a] benzimidazole-3-carboxamide were prepared. The formation of the compound was accomplished by cyclocondensation of 2-(1, 2-dihydro-2-oxo-1-phenyl-5-(pyridin-2-yl)pyridin-3-yl) benzaldehyde and N-(substituted phenyl)-3-oxobutanamide, 2-amino-benzimidazole under acid catalyzed conditions. The structures of pyrimidobenzimidazoles were determined by MASS, IR, <sup>1</sup>H NMR spectroscopic techniques & Elemental analysis technique.




\*Corresponding author: E-mail: joshi\_kaushik9@yahoo.com;

**Keywords:** Pyrimidobenzimidazoles; carboxamide; biomedical; biginelli; dimethylformamide.

## 1. INTRODUCTION

Heterocyclic compounds are important class of molecules in organic chemistry. They have been developed since many decades through chemists due to their significant role in medicinal chemistry and make available as a type pattern for the growth of a hodgepodge of therapeutic agents [1-3]. Nitrogen containing heterocycles are widely used amongst all heterocyclic moieties whether it is five or six member ring. Most biologically-active chemical entities contain a heterocycle. It means that heterocycles have vital role to impart in the drug designing section. Heterocycles can be applied to modify various properties of biologically active compounds like polarity, solubility, toxicity etc in the drug development phase. The large variety of heterocyclic compounds is available due to advance synthetic methodologies developed by many scientists. Heterocycles can also be isolated from natural sources and it can be modify as per the requirements. Medicinal chemists play significant role here to identify the lead compound from natural sources and modify their structures to impart some characteristics or decreases the toxic effects during drug discovery process.

Multicomponent reaction a way out because they are good organized cost resourceful and less profligate than straight process. The products of temperature quick to respond reactions from kinetic path can be selectively inaccessible. As multicomponent coupling often complex compound in a single step, they are extensively studied in the era of modern organic chemistry [4]. Poly substituted pyrimido [1, 2-a] benzimidazoles display a wide array of medicinal activities. They bear structural resemblance to purine bases.




**Fig. 1. Structure of pyrimido [1, 2-a] benzimidazole**

It serves as a trail to produce molecular environmental that combats the normally expensive and time-consuming drug detection process whereby a small number of novel therapeutics arrive at the market place. The added investigational benefits of generating multifaceted structures from easy raw materials without complex procedures, long-lasting purification procedures get better the synthetic approach for future youthful researchers wishing to donate products to a more systematically inventive civilization [5,6].

Pyrimidines have extensive and famed times gone by extending from the days of their judgment as significant part of nucleic acids to their present use in the AIDS chemotherapy.

Uracil, thymine and cytosine are the three important constituents of nucleic acids. Alloxan produces diabetes inducing reaction [7].

Pyrimidine class of compound are widely researched & employed as antibacterial agents [8]. Heterocycles bearing a benzimidazole moiety were reported to demonstrate a wide array of Medicinal properties like antimicrobial, anticonvulsant, anticancer, anti-inflammatory, analgesic, antidepressant, bioactivities, Antimicrobial, antimalarial, anticonvulsant, anticancer, anti-inflammatory, analgesic and antitubercular [9-17]. Some other experiments work done in our laboratory [16-20].



**Fig. 2. Structure of pyrimidine base compounds**

## 2. METHODOLOGY

An open capillary tubes method and uncorrected melting point were reported. Pattern of the compound was on the whole tartan by TLC on silica gel plates (0.51 mm) thickness and stain were situated by I<sub>2</sub> and Ultra Violate. Infrared spectra were documentation in Shimadzu instrument FTIR-8400 using KBr pellet method. Mass spectra were records on Shimadzu GC-MS-QP-2010 mold using express Injection probe method and Turbo spray model using chemical isolation technique. <sup>1</sup>H NMR was dogged in CDCl<sub>3</sub>/dimethyl sulfoxide solution on a Bruker Ac 400 MHz spectrometer.

### Common Methods for the preparation of N-(substitutedphenyl)-1,6-dihydro-[2,3'-bipyridin]-2-Methyl-4-(2-(6'-oxo-1'-phenyl-5'-yl)phenyl)-1,4-dihydro pyrimido[1,2-a]benzimidazole-3-carboxamide (VK- 501 to 510)

A combination of the 2-amino benzimidazole (0.01 M) N-(substitutedaryl)-3-oxo-4-methyl pentanamides (0.02 M) and 2-(1,2-dihydro-2-oxo-1-phenyl-5-(pyridin-2-yl) pyridin-3-yl) benzaldehyde (0.01 M) was heated to reflux in dimethylformamide (20 ml) for 24 hrs. After attaining the room temperature methanol (~25 mL) was supplementary. The reaction mass was kept for 12-14 hours and then filtered to give the 1,4-dihydro pyrimido[1,2-a]benzimidazoles (VK-501 to 510), which were crystallization from alcohol.

### N-(Phenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydropyrimido[1,2-a] benzimidazole-3-carboxamide (VK-501).

Yield: 65.3%; MP 170°C; Mass: m/z 627.

IR (cm<sup>-1</sup>): 3424 (νN-H secondary amide), 3094 (νC-H of aromatic ring), 2944 (νC-H asym of CH<sub>3</sub> group), 2849 (νC-H asym of CH<sub>3</sub> group), 1682 (νC=O of amide), 1594 (νN-H of pyrimidine ring), 1525 (νC=C of aromatic ring), 1454 (δ C-H asym of CH<sub>3</sub> group), 1345 (νC-H sym of CH<sub>3</sub> group), 1265 (νC-N), 742 (νC-H in plane of aromatic ring).

<sup>1</sup>H NMR (DMSO d<sub>6</sub>) δ ppm: 1.48 (s 3H, Ha), 5.26 (s 1H, Hb), 6.86-6.88 (m 2H, Hcd), 6.98-7.00 (dd' 2H, Hee), 7.05-7.07 (dd' 2H, Hff'), 7.12-7.15 (m 4H, Hg-j), 7.28-7.29 (dd' 2H, Hkk), 7.47-7.49 (dd' 2H, Hll'), 7.68-7.69 (t 4H, Hm-p), 7.83-7.84 (dd'

2H, Hqq'), 8.45-8.48 (m 3H, Hr-t); 8.70 (s 1H, Hu), 8.88-9.2 (s 1H, Hv).

### N-(4-Chlorophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro [2-3-bipyridin]-5-yl)-phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-502).

Yield: 57%; mp 187°C; MS: m/z 661.

IR (cm<sup>-1</sup>): 3252 (νN-H secondary amide), 3075 (νC-H of aromatic ring), 2952 (νC-H asym of CH<sub>3</sub> group), 2824 (νC-H asym of CH<sub>3</sub> group), 1652 (νC=O of amide), 1602 (νN-H secondary amide), 1556 (νC=C of aromatic ring), 1496 (νC-H asym of CH<sub>3</sub> group), 1365 (νC-H asym of CH<sub>3</sub> group), 1266 (νC-N), 695 (νC-H in plane of aromatic ring), 695 (νC-Cl stretch).

<sup>1</sup>H NMR (Dimethyl sulfoxide-d<sub>6</sub>) δ ppm: 1.50 (s 3H, Ha), 5.36 (s 1H, Hb), 6.82-6.87 (m 2H, Hcd), 7.0-7.3 (dd' 2H, Hee), 7.07-7.1 (dd' 2H, Hff'), 7.11-7.18 (m 4H, Hg-j), 7.26-7.30 (dd' 2H, Hkk), 7.41-7.42 (dd' 2H, Hll'), 7.66-7.69 (t 4H, Hm-p), 7.81-7.84 (dd' 2H, Hqq'), 8.46-8.49 (m 3H, Hr-t); 8.72 (s 1H, Hu), 8.81 (s 1H, Hv).

### N-(3-Chlorophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide(VK-503).

Yield: 63%; mp 188°C; MS: m/z 661.

IR (cm<sup>-1</sup>): 3360 (νN-H secondary amide), 3082 (νC-H of aromatic ring), 2957 (νC-H asym of CH<sub>3</sub> group), 2850 (νC-H asym of CH<sub>3</sub> group), 1670 (νC=O of amide), 1608 (νN-H of pyrimidine ring), 1561 (νC=C of aromatic ring), 1450 (νC-H asym of CH<sub>3</sub> group), 1394 (νC-H asym of CH<sub>3</sub> group), 1263 (νC-N), 742 (νC-H in plane of aromatic ring), 690 (νC-Cl stretch).

<sup>1</sup>H NMR (Dimethyl sulfoxide-d<sub>6</sub>) δ ppm: 1.49 (s 3H, Ha), 5.32 (s 1H, Hb), 6.84-6.87 (m 2H, Hcd), 7.2-7.3 (dd' 2H, Hee), 7.09-7.1 (dd' 2H, Hff'), 7.13-7.19 (m 4H, Hg-j), 7.27-7.31 (dd' 2H, Hkk), 7.44-7.45 (dd' 2H, Hll'), 7.67-7.70 (t 4H, Hm-p), 7.82-7.85 (dd' 2H, Hqq'), 8.45-8.49 (m 3H, Hr-t); 8.75 (s 1H, Hu), 8.80 (s 1H, Hv).

### N-(4-Bromophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide(VK-504).

Yield: 58%; mp 182°C; MS: m/z 706.

IR (cm<sup>-1</sup>): 3217 (νN-H secondary amide), 3082 (νC-H of aromatic ring), 2950 (νC-H asym of CH<sub>3</sub>

group), 2848 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1645 ( $\nu_{\text{C=O}}$  of amide), 1593 ( $\nu_{\text{N-H}}$  of pyrimidine ring), 1548 ( $\nu_{\text{C=C}}$  of aromatic ring), 1506 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1323 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1244 ( $\nu_{\text{C-N}}$ ), 745 ( $\nu_{\text{C-H}}$  in plane of aromatic ring), 690 ( $\nu_{\text{C-Br}}$  stretch).

$^1\text{H NMR}$  (Dimethyl sulfoxide- $d_6$ )  $\delta$  ppm: 1.52 (s 3H, Ha), 5.39 (s 1H, Hb), 6.87-6.89 (m 2H, Hcd), 7.3-7.5 (dd' 2H, Hee), 7.1-7.2 (dd' 2H, Hff'), 7.12-7.19 (m 4H, Hg-j), 7.26-7.30 (dd' 2H, Hkk), 7.43-7.45 (dd' 2H, Hll'), 7.65-7.70 (t 4H, Hm-p), 7.84-7.88 (dd' 2H, Hqq'), 8.47-8.51 (m 3H, Hr-t); 8.75 (s 1H, Hu), 8.86 (s 1H, Hv).

**N-(3-Bromophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-505).**

Yield: 55%; MP 178°C; MS:  $m/z$  706.

IR ( $\text{cm}^{-1}$ ): 3446 ( $\nu_{\text{N-H}}$  secondary amide), 3096 ( $\nu_{\text{C-H}}$  of aromatic ring), 2948 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 2805 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1705 ( $\nu_{\text{C=O}}$  of amide), 1633 ( $\nu_{\text{N-H}}$  of pyrimidine ring), 1528 & 1440 ( $\nu_{\text{C=C}}$  of aromatic ring), 1386 ( $\delta_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1300 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1256 ( $\nu_{\text{C-N}}$ ), 775 ( $\nu_{\text{C-H}}$  in plane of aromatic ring), 695 ( $\nu_{\text{C-Br}}$  stretch)

$^1\text{H NMR}$  (Dimethyl sulfoxide- $d_6$ )  $\delta$  ppm: 1.51 (s 3H, Ha), 5.38 (s 1H, Hb), 6.87-6.88 (m 2H, Hcd), 7.1-7.3 (dd' 2H, Hee), 7.09-7.1 (dd' 2H, Hff'), 7.13-7.19 (m 4H, Hg-j), 7.29-7.31 (dd' 2H, Hkk), 7.46-7.47 (dd' 2H, Hll'), 7.67-7.69 (t 4H, Hm-p), 7.83-7.87 (dd' 2H, Hqq'), 8.46-8.49 (m 3H, Hr-t); 8.75 (s 1H, Hu), 8.84 (s 1H, Hv).

**N-(4-Fluorophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-506).**

Yield: 62.82%; MP 189°C; MS:  $m/z$  645.

IR ( $\text{cm}^{-1}$ ): 3392 ( $\nu_{\text{N-H}}$  secondary amide), 3059 ( $\nu_{\text{C-H}}$  of aromatic ring), 2926 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 2847 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1647 ( $\nu_{\text{C=O}}$  of amide), 1591 ( $\nu_{\text{N-H}}$  of pyrimidine ring), 1548 & 1508 ( $\nu_{\text{C=C}}$  of aromatic ring), 1406 ( $\delta_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1340 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1271 ( $\nu_{\text{C-N}}$ ), 1026 ( $\nu_{\text{C-F}}$  stretch), 730 ( $\nu_{\text{C-H}}$  in plane of aromatic ring).

**N-(3-Fluorophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1,4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-507).**

Yield: 66%; MP 187°C; MS:  $m/z$  645.

IR ( $\text{cm}^{-1}$ ): 3300 ( $\nu_{\text{N-H}}$  secondary amide), 3001 ( $\nu_{\text{C-H}}$  of aromatic ring), 2933 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 2850 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1687 ( $\nu_{\text{C=O}}$  of amide), 1526 ( $\nu_{\text{N-H}}$  of pyrimidine ring), 1533 & 1465 ( $\nu_{\text{C=C}}$  of aromatic ring), 1344 ( $\delta_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1292 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1197 ( $\nu_{\text{C-N}}$ ), 1010 ( $\nu_{\text{C-F}}$  stretch), 748 ( $\nu_{\text{C-H}}$  in plane of aromatic ring).

**N-(4-Methylphenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-508).**

Yield: 63%; mp 183°C; MS:  $m/z$  641.

IR ( $\text{cm}^{-1}$ ): 3116 ( $\nu_{\text{N-H}}$  secondary amide), 3000 ( $\nu_{\text{C-H}}$  of aromatic ring), 2942 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 2856 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1627 ( $\nu_{\text{C=O}}$  of amide), 1528 ( $\nu_{\text{N-H}}$  of pyrimidine ring), 1454 & 1442 ( $\nu_{\text{C=C}}$  of aromatic ring), 1365 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1299 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1238 ( $\nu_{\text{C-N}}$ ), 774 ( $\nu_{\text{C-H}}$  in plane of aromatic ring)

**N-(4-Methoxyphenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-509).**

Yield: 61%; mp 184°C; MS:  $m/z$  657.

IR ( $\text{cm}^{-1}$ ): 3114 ( $\nu_{\text{N-H}}$  secondary amide), 3009 ( $\nu_{\text{C-H}}$  of aromatic ring), 2956 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 2894 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1657 ( $\nu_{\text{C=O}}$  of amide), 1576 ( $\nu_{\text{N-H}}$  of pyrimidine ring), 1518, 1502 & 1460 ( $\nu_{\text{C=C}}$  of aromatic ring), 1345 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1324 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group), 1257 ( $\nu_{\text{C-N}}$ ), 731 ( $\nu_{\text{C-H}}$  in plane of aromatic ring).

**N-(4-Nitrophenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydro pyrimido[1,2-a] benzimidazole-3-carboxamide (VK-510).**

Yield: 71%; mp 181°C; MS:  $m/z$  672.

IR ( $\text{cm}^{-1}$ ): 3390 ( $\nu_{\text{N-H}}$  secondary amide), 3028 ( $\nu_{\text{C-H}}$  of aromatic ring), 2936 ( $\nu_{\text{C-H}}^{\text{asym}}$  of  $\text{CH}_3$  group)

CH<sub>3</sub> group), 2853 ( $\nu$ C-H asym of CH<sub>3</sub> group), 1687 ( $\nu$ C=O of amide), 1611 ( $\nu$ N-H of pyrimidine ring), 1532, & 1446 ( $\nu$ C=C of aromatic ring), 1364 ( $\nu$ C=C of Aromatic ring), 1333 ( $\nu$ C-H sym of CH<sub>3</sub> group), 1275 ( $\nu$ C-N), 1275 ( $\nu$ C-N), 750 ( $\nu$ C-H in plane of Aromatic ring)


### 3. RESULTS AND DISCUSSION

The bioactivity potential of 1, 4-dihydropyrimido [1, 2-a] benzimidazoles is widely reported. Further, diversely substituted derivatives of this class of compound have depicted impressive medicinal profile.

Man-made ways to 1, 4-dihydropyrimido [1, 2-a] benzimidazoles is pedestal on the **Biginelli** like

cyclo combination of new -CHO and N- (substituted phenyl)-3-oxobutanamide with 2-amino benzimidazole.

Noting a range of claim biomedical and with a view further to deem the Medicinal profile of this set of compound, narrative series of N- (substituted phenyl)-2-methyl-4-(2-(6-oxo-1-phenyl-1-6-dihydro-[2-3-bipyridin]-5-yl)phenyl)-1-4-dihydropyrimido[1,2-a] benzimidazole-3-carboxamide (VK-501 to VK-510) were manufactured. The manufacture of (VK-501 to VK-510) were achieved by reaction of N- (substituted phenyl)-3-oxobutanamide, 2-aminobenzimidazole and 2-(1,2-dihydro-2-oxo-1-phenyl-5-(pyridin-2-yl)pyridin-3-yl)benzaldehyde in the presence of HCl.




**Scheme 1. Reaction scheme of pyrimidine derivatives**

**Table 1. Physical data**

Code	R	Molecular formula	Molecular Weight	Melting Point °C	R <sub>f</sub>	Yield
VK-501	H	C <sub>40</sub> H <sub>30</sub> N <sub>6</sub> O <sub>2</sub>	627	170	0.43	64
VK-502	4-Cl	C <sub>40</sub> H <sub>29</sub> ClN <sub>6</sub> O <sub>2</sub>	661	187	0.44	57
VK-503	3-Cl	C <sub>40</sub> H <sub>29</sub> ClN <sub>6</sub> O <sub>2</sub>	661	188	0.50	63
VK-504	4-Br	C <sub>40</sub> H <sub>29</sub> BrN <sub>6</sub> O <sub>2</sub>	706	182	0.49	58
VK-505	3-Br	C <sub>40</sub> H <sub>29</sub> BrN <sub>6</sub> O <sub>2</sub>	706	178	0.43	55
VK-506	4-F	C <sub>40</sub> H <sub>29</sub> FN <sub>6</sub> O <sub>2</sub>	645	189	0.44	62
VK-507	3-F	C <sub>40</sub> H <sub>29</sub> FN <sub>6</sub> O <sub>2</sub>	645	187	0.46	66
VK-508	4-Me	C <sub>41</sub> H <sub>32</sub> N <sub>6</sub> O <sub>2</sub>	641	183	0.40	63
VK-509	4-OMe	C <sub>41</sub> H <sub>32</sub> N <sub>6</sub> O <sub>3</sub>	657	184	0.50	61
VK-510	4-NO <sub>2</sub>	C <sub>40</sub> H <sub>29</sub> N <sub>7</sub> O <sub>4</sub>	672	181	0.47	71

### 3.1 Plausible Reaction Mechanism



**Scheme 2. Plausible reaction mechanism**

### 4. CONCLUSION

In conclusion, Our study commenced with different types of N-(substituted phenyl)-3-oxobutanamide, 2-aminobenzimidazole, two new special kind of aldehyde as 4-(4-(trifluoromethyl)-2-nitrophenoxy)-2-hydroxybenzaldehyde and 2-(1,2-dihydro-2-oxo-1-phenyl-5-(pyridin-2-yl)pyridin-3-yl)benzaldehyde in presence of DMF (N,N'-Dimethyl formamide) as solvent. The reaction proceeds with fast rate and yields good to high percentage of product. Structure were elucidated by IR, mass and NMR.

### ACKNOWLEDGEMENT

Author is thankful to Department of Chemistry, D. K. V. Arts and Science College, Jamnagar, India for providing laboratory facilities. None of the author working under any project.

### COMPETING INTERESTS

Authors have declared that no competing interests exist.

### REFERENCES

- White A, C, Black RM. US Patent 3, 1997, 989, 709; Chemical Abstract. 1977;86:72694c.
- Vartale P, SP, Ubale PN, Sontakke SG, Halikar NK, Pund MM. Antioxidant and antimicrobial evaluation of pyrimido [1, 2-a] benzimidazoles. World Journal of Pharmaceutical Sciences, 2014;2;:665–670.
- Forche Asobo P, Wahe H, Mbafor JT, Nkengfack AE, Fomum ZT, Sopbue EF, Döpp D. Heterocycles of biological importance. part 5. the formation of novel biologically active pyrimido [1,2-a] benzimidazoles from allenic nitriles and aminobenzimidazoles. Journal of the Chemical Society, Perkin Transactions. 2001;1:457–461. Available:https://doi.org/10.1039/B005511P
- Haas CP, Tallarek U. Kinetics studies on a multicomponent knoevenagel–michael domino reaction by an automated flow reactor. Chemistry Open. 2019;8:606-614. Available:https://doi.org/10.1002/open.201900124
- Chandra Kant Belwal, Kaushik A Joshi. Synthesis and antimicrobial screening of 2-[(5,6-dimethoxy-2,3-Dihydro-1h-inden-1-ylidene)hydrazinylidene]-1,3-thiazolidin-4-one and its 5-arylidene derivatives. Heterocyclic Letters. 2014;4(1):65-71.
- Chauhan V, Joshi KA, Ram HK. Synthesis of Novel schiff base of 3-(2, 4-Disulfamoylaniline) morpholine derivatives.

- International Journal For Pharmaceutical Research Scholars. 2015;4(4):178-182.
7. Goldner MG, Spengel G. On the transmission of alloxan diabetes and other diabetogenic influences. *Adv, Metabolic Disorder.* 1972;6:57-72. Available: <https://doi.org/10.1016/B978-0-12-027306-5.50007-3>
  8. Mohamed MS, Awad SM, Sayed AI. *Molecules.* 2010;15:1882-1890. Available: <https://doi.org/10.3390/molecules15031882>
  9. Kumari NS, Lingappa B, Girisha KS, Rai S, Kalluraya BN. *Ind J Chem.* 2008;47B:1858-1864.
  10. Gitto R, Caruso R, Orlando V, Quartarone S, Barreca ML, Ferreri G, Russo E, Sarro G, Chimirri A. *IL FARMACO.* 2004;59:7-12. Available: <https://doi.org/10.1016/j.farmac.2003.10.003>
  11. Shrivastava N, Naim MJ, Alam MJ, Nawaz F, Ahmed S, Alam O. *Arch. Pharm. Chem. Life Sci.* 2017;350:e1700040. Available: <https://doi.org/10.1002/ardp.201700040>
  12. Gaba M, Gaba P, Uppal D, Dhingra N, Bahia MS, Silakari O, Mohan C. Benzimidazole derivatives: Search for GI-friendly anti-inflammatory analgesic agents. *Acta Pharm Sin B.* 2015;5:337-342. Available: <https://doi.org/10.1016/j.apsb.2015.05.003>
  13. Gaba M, Singh S, Mohan C. Benzimidazole: An emerging scaffold for analgesic and anti-inflammatory agents. *Eur. J. Med. Chem.* 2014;76:494-505. Available: <https://doi.org/10.1016/j.ejmech.2014.01.030>
  14. Araujo DML, Maste MM, Alegaon S, Saxena A. Synthesis, antitubercular evaluation and docking studies of novel benzimidazole analogues. *IJPSR.* 2018;9:3696-3704. DOI:10.13040/IJPSR.0975-8232.9(9).3696-04
  15. Dokla EME, Abutaleb NS, Milik SN, Li D, Elbaz K, Shalaby MA, Al-Karaki R, Nasr M, Klein CD, Abouzid KAM, Seleem MN. *E. J. Med. Chem.* 2020;186:111850. Available: <https://doi.org/10.1016/j.ejmech.2019.111850>
  16. Siddiqui N, Alam Md. S, Sahu M, Yar MS, Alam O, Siddiqui Md. JA. Antidepressant, analgesic activity and SAR studies of substituted benzimidazoles. *Asian J. Pharm. Res.* 2016;6:170-174. DOI: 10.5958/2231-5691.2016.00024.1
  17. Kuchekar B, Pore Y. *Dig. J. Nanomater Bios.* 2008;3:293-298.
  18. Joshi KA, Makwana NR. Synthesis and biological screening of N-((2-(4-Fluorophenyl)-6-methylimidazo[1,2-A]Pyridin-3-Yl)Methyl)-4-arylamines. *International Journal for Innovative Research in Multidisciplinary Field.* 2019;7:16-21.
  19. Joshi VN\*, Joshi KA, Modhavadiya VA. Synthesis and characterization of fluoropyrimidine derivatives. *European Journal of Biomedical and Pharmaceutical sciences.* 2017;4(12):374-377.
  20. Kaushik A, Joshi\*, Haresh K Ram. Synthesis a number of unimpeachable pyrimidine derivatives. *International Journal of Applied Chemistry.* 2017; 13(1):135-140.

© 2022 Joshi et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*  
The peer review history for this paper can be accessed here:  
<https://www.sdiarticle5.com/review-history/81384>